{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"62.3","upperLimit":"72.4","value":"68"},{"groupId":"OG001","lowerLimit":"47.2","upperLimit":"57.9","value":"53"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"351"},{"groupId":"OG001","value":"350"}],"units":"Participants"}],"description":"Overall response was defined as the percentage of confirmed responders (complete response \\[CR\\] + partial response \\[PR\\] per RECIST, Version 1.1) as summarized by Investigator assessment. CR was defined as the disappearance of all evidence of target lesions. PR was defined as at least a 30% reduction from Baseline in the sum of the longest diameter (LD) of all target lesions. Data were reported as those participants with measureable disease at Baseline.","dispersionType":"95% Confidence Interval","groups":[{"description":"Dabrafenib 150 milligrams (mg) orally twice daily (BID) and Trametinib 2 mg orally once daily until disease progression, death, unacceptable toxicity, or withdrawal of consent.","id":"OG000","title":"Dabrafenib Plus Trametinib"},{"description":"Vemurafenib 960 mg orally BID until disease progression, death, unacceptable toxicity, or withdrawal of consent.","id":"OG001","title":"Vemurafenib"}],"paramType":"NUMBER","populationDescription":"Intent-to-Treat (ITT) Population. Only participants with measurable disease at baseline were included.","reportingStatus":"POSTED","timeFrame":"From randomization until the first documented complete response or partial response (up to approximately 6 years)","title":"Overall Response Rate (ORR) During Randomized Phase, as Assessed by the Investigator","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}